Triple Negative Breast Cancer
A comprehensive guide to understanding Triple Negative Breast Cancer: from diagnosis to cutting-edge treatments
Understanding Triple Negative Breast Cancer: The Basics
Triple Negative Breast Cancer (TNBC) represents one of the most challenging forms of breast cancer to treat, yet recent advances in medical research are bringing new hope to patients and their families. Triple-negative breast cancer (TNBC) accounts for about 10-15% of all breast cancers, making it a significant concern in oncology practice.
Triple-negative breast cancer is an aggressive type of breast cancer that can be hard to treat and often comes back. The term “triple negative” refers to the absence of three specific receptors that are commonly found in other breast cancers:
This unique characteristic makes TNBC distinct from other breast cancer subtypes and significantly impacts treatment approaches, as many standard hormonal therapies and targeted treatments are ineffective against this form of cancer.
The statistics surrounding TNBC reveal important patterns that help us understand who is most at risk:
Triple-negative breast cancer accounts for approximately 15% to 25% of all breast cancers. Based on data from 2021, in the United States (US) the overall age-adjusted incidence of triple-negative breast cancer is 14.5 cases per 100,000 women.
Racial and Ethnic Disparities:
Non-Hispanic Black women are most likely to be diagnosed with TNBC compared to other racial groups. 1 in 5 Black women with breast cancer are diagnosed with triple-negative breast cancer, which is harder to treat. This is higher than any other racial or ethnic group.
Age Factors:
Premenopausal women and women under the age of 50 have an increased risk of developing TNBC. This younger age of onset is one of the distinguishing characteristics that sets TNBC apart from other breast cancer types.
The survival statistics for TNBC vary significantly depending on the stage at diagnosis:
Early-Stage TNBC: Although research suggests that about 40% of people who receive treatment for stages 1 to 3 of TNBC will experience a recurrence, 60% will continue to live a disease-free survival.
Advanced TNBC: Metastatic triple-negative breast cancer is an aggressive cancer with an average survival of 8 to 13 months, though survival for patients newly diagnosed with metastatic (stage IV) triple-negative breast cancer is about 1 ½ to 2 years with current treatments.
Five-Year Survival: In the United States, TNBC is responsible for 12% of breast cancers, with a 5-years survival rate of 8–16% for metastatic disease, though early-stage survival rates are significantly better.
TNBC often presents with symptoms similar to other breast cancers, but Triple-negative breast cancer is a fast-growing form of breast cancer, which means symptoms may develop more rapidly than with other types.
Physical Changes:
Advanced Symptoms:
Due to the aggressive nature of TNBC, early detection is crucial. Triple-negative breast cancer (TNBC) represents a particularly aggressive and heterogeneous subtype of breast cancer, associated with poor prognosis and limited treatment options. However, when caught early, treatment outcomes improve significantly.
The connection between genetic mutations and TNBC is one of the most significant risk factors:
BRCA Mutations: We’ve known that mutations in the BRCA1 and BRCA2 genes are linked with an increased risk for breast cancer. Now we know 5 other genes associated with a high risk for triple-negative breast cancer (TNBC).
Some women with triple negative breast cancer also have a fault (mutation) in the BRCA1 or BRCA2 genes. BRCA stands for Breast Cancer gene. Everyone has BRCA1 and BRCA2 genes. They stop cells in our body from growing and dividing out of control.
Implications for Families: Women with BRCA1 mutations have a significantly higher lifetime risk of developing TNBC. CBC incidence at 60, 120, and 150 months was significantly higher in BRCA1/2 mutation carriers compared to non-carriers.
Age Distribution: The risk is 4.2% among women aged less than 40 years. It was also noted that when the duration of oral contraceptive use increased, the risk increased.
Lifestyle and Environmental:
Reproductive History:
Out of these, chemotherapy is the most established treatment for TNBC. Unlike hormone receptor-positive breast cancers that can be treated with hormonal therapies, TNBC requires more aggressive approaches.
Neoadjuvant Chemotherapy:
Adjuvant Chemotherapy:
If TNBC comes back (recurs) locally, cannot be removed with surgery, and makes the PD-L1 protein, immunotherapy with the drug pembrolizumab along with chemotherapy is an option.
Key Immunotherapy Advances: immune checkpoint inhibitors, for example, pembrolizumab, atezolizumab, and durvalumab, are widely explored for TNBC treatment.
Recent studies show promising results: A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.
PARP Inhibitors: Targeted therapies, including PARP inhibitors, immune checkpoint inhibitors, and EGFR inhibitors, hold promise for personalized treatment approaches. These drugs are particularly effective in patients with BRCA mutations.
Antibody-Drug Conjugates (ADCs): Sacituzumab govitecan is the next game-changer for treating metastatic triple-negative breast cancer with 2X longer survival rates than the single-agent chemotherapies.
Other Targeted Approaches: These include PI3K/AKT/mTOR inhibitors, epidermal growth factor receptor inhibitors, Notch inhibitors, poly ADP-ribose polymerase inhibitors, and antibody–drug conjugates.
The therapeutic strategies include immunotherapy and various molecular targeted therapies, including intracellular pathway inhibitors, cell cycle inhibitors, and AR inhibitors.
Multi-Modal Approaches: interventions have been highlighted and include chemotherapy, immunotherapy, radiotherapy, stem cell therapy, laser treatment, hyperthermia, surgery, and photodynamic therapy.
The Treatment Journey: What Patients Can Expect
Initial Evaluation:
Molecular Testing:
Multidisciplinary Team Approach:
Breast-Conserving Surgery:
Mastectomy:
Short-term Recovery:
Long-term Surveillance:
Surveillance Strategies:
Risk Reduction Options:
Precision Medicine:
Novel Therapeutic Approaches:
Triple-negative breast cancer (TNBC) was first described as a distinct disease entity 20 years ago. Since that time, there has been tremendous effort invested in understanding the clinical features and biology of this breast cancer subtype and developing effective treatments.
Despite the challenges, Despite the approval of new TNBC targeted therapies, only a month increase of the 5-year survival rate was observed, researchers continue to make significant strides in understanding and treating this complex disease.
The waiting room is always the hardest part. Not the test itself, not even the…
Our ears play a vital role in communication, balance, and overall awareness of the world…
Constipation is a common digestive problem that affects people of all ages. Some experience it…
More than 537 million adults worldwide are living with diabetes, a number projected to surge…
Every 3 minutes, someone in India gets into a road accident. Every 15 minutes, someone…
Screens have become an unavoidable part of modern life. From smartphones and laptops to televisions…